Immune and Metabolic Effects of Antigen-Specific Immunotherapy Using Multiple β-Cell Peptides in Type 1 Diabetes.

"Duality of Interest. Y.-F.L. has consulted for UCB Pharma. M.P. has consulted for UCB Pharma and benefits from a license agreement with King’s College London. T.T. has received speaker fees from UCB Pharma. No other potential conflicts of interest relevant to this article were reported."

"Funding. This research was funded/supported by the National Institute for Health Research (NIHR) Biomedical Research Centre based at Guy’s and St. Thomas’ NHS Foundation Trust and King’s College London and/or the NIHR Clinical Research Facility. Flow cytometry studies were supported by the T1DUK Immunotherapy Consortium funded by Diabetes UK (grants 15/0005232 and 15/0005233). The study was cosponsored by King’s College London and Guy’s and St. Thomas’ NHS Foundation Trust. UCB Pharma provided grant funding and input into the study design, outcome analysis, and data interpretation."